N-(1-methanesulfonyl piperidin-4-yl)-N'-(adamant-1-yl)urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-methanesulfonyl piperidin-4-yl)-N'-(adamant-1-yl)urea
• 英文别名: 1-adamantyl-3-(1-(methylsulfonyl)piperidin-4-yl)urea；1-(1-Adamantyl)-3-(1-methylsulfonylpiperidin-4-yl)urea
• 化学式: C₁₇H₂₉N₃O₃S
• 分子量: 355.502
• InChiKey: DBPGHZGPUBWOQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  异氰酸1-金刚烷酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 42.0h， 生成 N-(1-methanesulfonyl piperidin-4-yl)-N'-(adamant-1-yl)urea
  参考文献：
  名称：

  1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia

  摘要：

  1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an intraperitoneal glucose tolerance test. AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats. These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the observed pharmacology in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.042

文献信息

• CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
  申请人：Hammock D. Bruce

  公开号：US20070225283A1

  公开（公告）日：2007-09-27

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了可抑制可溶性环氧化物水解酶（sEH）的抑制剂，这些抑制剂结合了多种药效团，并且在治疗疾病方面具有用途。
• USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS
  申请人：Webb Hsu Heather K.

  公开号：US20090270452A1

  公开（公告）日：2009-10-29

  Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome.

  本文揭示了一种通过给予可溶性环氧化物水解酶抑制剂来增强受试者平滑肌功能的化合物、组合物和方法，并用于治疗患有平滑肌障碍的受试者，包括勃起功能障碍、膀胱过度活跃、子宫收缩和肠易激综合征。
• PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS
  申请人：Gless Richard D.

  公开号：US20080207908A1

  公开（公告）日：2008-08-28

  Disclosed are processes for the synthesis of piperidinyl-substituted urea compounds. This invention further relates to novel intermediates prepared during this synthesis.

  本发明涉及合成哌啶基取代的脲类化合物的过程。此外，本发明还涉及在该合成过程中制备的新型中间体。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
  申请人：Hsu Heather Kay Webb

  公开号：US20080221104A1

  公开（公告）日：2008-09-11

  Methods for reducing autoimmune induced inflammation, including rheumatoid arthritis in a subject in need of such therapy are disclosed.

  公开了用于减少自身免疫引起的炎症的方法，包括治疗需要这种治疗的类风湿性关节炎患者的方法。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS
  申请人：Hsu Heather Kay Webb

  公开号：US20080221105A1

  公开（公告）日：2008-09-11

  Compounds, compositions, and methods for inhibiting the onset of metabolic syndrome and treating related disorders in a subject in need of such therapy are disclosed.

  本发明揭示了用于抑制代谢综合征的发生和治疗相关疾病的化合物、组合物和方法，适用于需要此类治疗的受试者。